개요
엑소좀은 엔도솜에서 유래한 세포외 소포(EV)로, 크기는 30-150 나노미터입니다. 거의 모든 유형의 세포에서 분비되는 엑소좀은 세포 특이적인 단백질, 지질, 핵산을 운반하고 수용 세포에 선택적으로 흡수되어 세포 간 소통에 중요한 역할을 합니다.
최근 엑소좀 기술의 발전으로 액체생검, 정밀의료, 재생의료 분야에서 엑소좀의 활용이 확대되고 있습니다. 특히 암 유래 엑소좀은 혈관신생, 전이, 면역을 조절하는 능력으로 가치가 높으며, 암의 발견, 진단, 치료법 선택에 매우 중요합니다.
엑소좀 카고는 암뿐만 아니라 심혈관질환, 신장질환, 신경퇴행성 질환, 대사성 질환 등 다양한 질환의 예후에 대한 지식을 제공합니다. 엑소좀 내에 수많은 생체 분자가 존재한다는 사실이 밝혀지면서 암의 검출, 모니터링, 치료를 위한 암 바이오마커로 활용하기 위한 광범위한 조사가 활발히 진행되고 있습니다.
엑소좀은 혈청, 혈장, 소변, 타액 등 다양한 생체액에 존재하므로 저침습적 진단에 이상적입니다. 또한 예후 지표 및 치료 효과의 예측 인자로도 작용합니다. 또한 엑소좀의 치료적 응용도 연구되고 있습니다. 예를 들어 엑소좀은 결함이나 결손 분자로 인한 질병을 표적 치료하기 위해 치료용 siRNA나 단백질을 운반하도록 설계될 수 있습니다. 간엽줄기세포(MSC) 유래 엑소좀은 염증을 억제하고, 흉터 조직 형성을 방지하며, 면역반응을 조절할 수 있는 가능성을 보여주고 있습니다.
과소평가되었던 엑소좀 분야는 현재 급속도로 발전하고 있습니다. 최근 논문에서 미국 저자와 중국 연구자들의 성과가 두드러지며, 특히 Karolinska Institutet의 Susanne Gabrielsson 박사와 Unicyte AG가 관련 과학 문헌을 주도하고 있습니다.
BioInformant의 세계 전략 보고서는 특허, 보조금, 출판물, 임상시험 동향 등 급성장하는 엑소좀 시장을 자세히 설명합니다. 업계내 제휴, 인수합병(M&A), 자금 조달, 경쟁 구도 및 2030년까지 시장 전망도 함께 다루고 있습니다.
엑소좀을 이용한 진단 및 치료제가 확대되고 있으며, 현재 388건의 임상시험이 진행 중입니다. 엑소좀 치료제는 아직 판매 승인을 받지 못했지만, 2029년까지 첫 5가지 제품이 출시될 것으로 예상됩니다. 엑소좀은 표적에 대한 전달, 부작용 감소, 면역 검출 회피 등 기존 치료법에 비해 유망한 이점을 제공합니다.
엑소좀은 의료용 외에도 피부 회춘, 상처 치유, 흉터 교정, 모발 재생을 촉진하기 위해 화장품에도 사용되고 있습니다. 엑소좀 기반 진단약 2종은 이미 미국 FDA로부터 패스트트랙 승인을 받은 바 있습니다.
이 종합 보고서는 다음과 같은 정보를 제공합니다. :
- 시장 분석 : 엑소좀 치료제/진단제, 제품/서비스, 제조기술, 화장품 용도
- 엑소좀 치료제 임상시험 파이프라인(미감작 및 인공 엑소좀 포함)
- 엑소좀 진단법을 활용한 승인된 제품 및 향후 출시 예정 제품
- 임상시험 활동: 유형별, 지역별, 상권별, 투자자별, 임상시험 활동
- 주요 산업 지표 분석 : 과학 논문, 특허, 보조금, 임상시험 등
- 주요 자금조달 이벤트(M&A, 자금조달 이벤트, 공동개발 계약, IPO 포함)
- 전략적 파트너십과 경쟁 인사이트사항
- 시장 규모(시장 부문별, 지역별) 및 예측(-2030년)
- 업계 동향 및 향후 방향성
이 보고서는 엑소좀 치료제 및 진단, 연구 제품, 제조 기술, 화장품, RTU(Ready-to-Use) 엑소좀을 개발하는 기업에게 시장 정보를 제공하는 것을 목적으로 합니다. 엑소좀 시장에는 많은 경쟁자들이 존재하므로 이 보고서는 많은 시간을 들여 조사하지 않고도 정보를 얻고 기회를 포착할 수 있는 귀중한 리소스를 제공합니다.
목차
제1장 조사 개요
제2장 엑소좀 생물학과 기능 : 개요
- 엑소좀 구조
- 엑소좀 분자 함유량
- 엑소좀 막과 내강 컴포넌트
- 엑소좀 유래에 의한 분류
- 합성 엑소좀
- 세포치료와 유전자 치료의 차이
- 세포치료로부터 엑소좀 요법으로의 이동
- 향후 10년간 엑소좀
제3장 엑소좀 엔지니어링 : 새로운 기술 플랫폼
- 내부 수식
- 분리전 내부 수식 방법
- 인큐베이션
- 유전자 편집
- 분리 후 내부 수식 방법
- 표면 개질
- 친세포에 의한 표면 개질
- 직접 표면 개질
- 엑소좀 안 분자 표시
- 내부 수식
- 표면·내부 개질 엑소좀
제4장 엑소좀에 관한 과학 간행물
- 엑소좀 진단법·치료법 출판 동향
- 주요 기술에 의한 치료용 엑소좀에 관한 PubMed 간행물
- PubMed 엑소좀 분리와 정제에 관한 기술 논문
- 약물 캐리어로서의 지질 나노입자와 엑소좀에 관한 PubMed 논문
- 엑소좀 간행물 분포 : 질환 유형별
- 엑소좀 간행물 : 암 유형별
제5장 엑소좀 특허의 개요
- 엑소좀 특허 공개 추이
- 엑소좀 특허 : 치료용과 진단용
- 엑소좀 특허 출원 : 엑소좀 공급원별
- 특허/특허 출원 : 분리·정제 기술별
- 특허/특허 출원 : 카고 유형별
- 특허/특허 출원 : 카고 적재 방법별
- 특허/특허 출원 : 치료 분야별
- 엑소좀 특허의 주요 양수인
- 특허 취득 끝난 분리·조제 기술의 유형 : 양수인별
- 양수인이 사용하는 카고 유형
- 카고 적재 방법 : 양수인별
- 치료 영역 : 양수인별
- 양수인 카테고리
- 엑소좀 특허 출원 건수 : 관할 지역별
- 엑소좀 특허 출원인
- 엑소좀 특허 발명자
- 엑소좀 특허 소유자
- 엑소좀 특허 법적 지위
제6장 엑소좀 : 임상시험의 상황
- 엑소좀 임상시험 : 연구 단계별
- 엑소좀 임상시험 : 자금 제공자 유형별
- 엑소좀 임상시험 : 기술별
- 엑소좀을 이용한 질환 치료의 임상시험 현황
- 진단 연구을 위한 엑소좀을 이용한 임상시험
- 주요 엑소좀 연구개발 기업
- 전임상 개발중인 엑소좀 치료제
제7장 엑소좀 분리/정제 기술 : 개요
- 초원심분리(UC)
- 한외여과(UF)
- 사이즈 배제 크로마토그래피(SEC)
- 폴리머 침전법
- 면역 친화성 포착법
- 압타머 기반 방법
- 마이크로 유체 기술
제8장 엑소좀 기업의 독자 기술 플랫폼
- 선택된 엑소좀 기술 플랫폼 해설
- AGLE-102
- Hybridosome
- AB126
- CAP-1002(Deramiocel)
- REGENT
- ExoFlo
- DeliverEX
- EXOVEX
- ExoSCRT
- LEAP
- ExoDx
- EXPLOR
- Exo-Target
제9장 엑소좀 엔지니어링 기술 : 개요
- 부화법
- 트랜스펙션법
- 초음파 처리법
- 일렉트로포레이션법
- 압출법
- 동결 융해법
- 유전자 엔지니어링적 방법
제10장 엑소좀 치료에 대한 응용 : 개요
- 엑소좀 치료 분야의 주요 기업
- Nano24 EXO-CD24(OBCTCD24)
- The Hemopurifier
- Carmine Therapeutics REGENT
- Ciola 엑소좀 커스터마이즈 기술
- Capricor Therapeutics CAP-1002(Deramioce)
- ILIAS Biologics EXPLOR
- Aruna Bio AB126
- Aegle Therapeutics AGLE-102
- OmniSpirant Therapeutics OmniSomes
- Exogenus Therapeutics EXO-101
- RION 정제 엑소좀 제품(PEP)
제11장 엑소좀의 진단에 대한 응용
- 진단 용도 이점
- 진단에 중점을 두는 주요 적응증
- 가장 일반적인 표적 엑소좀 바이오마커
- 진단 용도 엑소좀 단백질
- 암 진단약으로서의 엑소좀 miRNA
- 진단용 엑소좀 연구
- 엑소좀 진단약의 개발 주요 기업
- BioFluidica LiquidScan
- ExoCan ExoEnrich
- Exosome Diagnostics, Inc.ExoDx 전립선 검사
- 엑소좀 사이언스 타우솜 검사
- Exosomics SpA에 의하지만 진단
- Guardant Health Guardant360 CDx
- Mursla Bio에 의한 간암 탐지 연구
- NanoSomiX BDE 바이오마커 어세이
- Theoria Science ExoScreen 어세이
제12장 미용 엑소좀 응용
- 미용 엑소좀 치료
- 얼굴 회춘의 엑소좀
- 육모의 엑소좀
- 흉터 경감의 엑소좀
- 유방확대수술의 엑소좀
- 미용 목적 엑소좀 공급원
- 피부과학에 관련된 엑소좀 과학
- 주요 기업과 제품
- 인기 엑소좀 기반 미용
- AnteAGE Pro 시스템
- Cartessa ExoCR
- ELEVAI Labs ELEVAI enfinity
- Exoceuticals EXO PLUS
- Kimera Labs Vive
- RION Aesthetics CALM Serum
- ExoCoBio ASCE Exosomes
제13장 엑소좀 분야 거래와 자금조달
- 엑소좀 기업에 대한 벤처캐피털 자금
- EXO Biologics
- Exogenus Therapeutics
- INEXOPLAT
- Mantra Bio
- Anjarium Biosciences
- Evox Therapeutics, Ltd.
- ILIAS Biologics
- ExoCoBio, Inc.
- Aegle Therapeutics
- Evox Therapeutics
- Evox Therapeutics
- Codiak BioSciences
- Codiak BioSciences
- Exosome Diagnostics
- Exosome Diagnostics, Inc
- EXO 바이오로지크스
- 엑소좀 분야 파트너십 계약
- Cytiva와 Rooster Bio
- SomesTech와 ConvEyXO
- RoosterBio, Inc.(와)과 FUJIFILM Diosynth Biotechnologies
- Evox Therapeutics와 Eli Lilly
- Exopharm와 Astellas
- Univercells Technologies와 RoosterBio
- AgeX Therapeutics와 UCI
- VivaZome와 La Trobe University
- Evotec SE와 Curexsys GmbH
- Bio-Techne와 QIAGEN
- InnoCan Pharma와 Recipharms
- Codiak BioSciences와 Sarepta
- Evox Therapeutics와 Takeda
- PureTech와 Roche
- Evox Therapeutics와 Boehringer Ingelheim
- Sarpeta Therapeutics와 Codiak Biosciences
- Navigo Proteins와 MDimune
- Jazz Pharmaceuticals와 Codiak BioSciences
- Exosome Diagnostics와 Intezyne
- Evox Therapeutics와 Boehringer Ingelheim
- 기업 인수 거래
- ExoCoBio와 BENEV
- Evox Therapeutics와 Codiak Biosciences' Technology
- Lonza와 Exosomics
- Lonza와 Codiak Biosciences
- Bio-Techne Corporation와 Exosome Diagnostics
- Lonza와 HansaBioMed
- 라이선스 거래
- EVerZom와 Erganeo
- Elevai Labs와 Yuva Biosciences
- TOPPAN와 Dai Nippon Toryo
- Carnegie Mellon University(CMU)와 Coya Therapeutics
- INOVIQ, Ltd.(와)과 ResearchDx, Inc.
- ATUM와 Codiak BioSciences
- Johns Hopkins University와 Capricor Therapeutics
- Evox Therapeutics와 Eli Lily
- Codiak BioSciences와 Sarepta
- VivaZome Therapeutics와 University of Adelaide
- Evox Therapeutics와 Takeda
- CEVEC와 Evox Therapeutics
- Orgenesis와 Excella Bio
- System Biosciences와 QIAGEN
- PureTech Health와 3D Biotechnologies
- 신규 주식 공개
- Elevai Labs
- Codiak Biosciences
- Codiak Biosciences
- Codiak BioSciences
제14장 엑소좀 시장 분석
- 엑소좀 치료제 시장
- 세계의 RTU(Ready-to-Use) 정제 엑소좀 시장 : 유형별
- 엑소좀 진단약 시장
- 세계의 엑소좀 기술 시장 : 제품 유형별
- 세계의 엑소좀 기반 미용품(화장품) 시장
- 엑소좀 시장 전체
- 엑소좀 요법 시장 촉진요인
제15장 엑소좀 시장의 경쟁사의 개요
- 101 Bio
- Abbexa, Ltd.
- AcouSort AB
- Aegle Therapeutics
- Aethlon Medical, Inc.
- Akrivis Health Care Pvt., Ltd.
- AM BioTech
- AMS Biotechnology, Ltd.(AMSBIO)
- AnteAGE
- Aposcience AG
- Aruna Bio
- BENEV Company, Inc.(ExoCoBio)
- BioCat GmbH
- BioFluidica
- Biological Dynamics, Inc.
- Biorbyt, Ltd.
- Bioscience Institute
- Biosynth International, Inc.
- BreStem Therapeutics, Inc.
- Capricor Therapeutics
- Carmine Therapeutics
- Cellarcus Biosciences, Inc.
- Cell Care Therapeutics
- Cells for Cells
- Cell Guidance Systems, Ltd.
- Ciloa
- ConvEyXO
- Craif, Inc.
- Creative Bioarray
- Creative Biostructure
- Creative Biolabs
- Creative Medical Technology Holdings, Inc.
- Creative Proteomics
- CUSABIO Technology LLC
- Diadem Biotherapeutics
- Direct Biologics
- Elevai Labs, Inc.
- Entelexo Biotherapeutics
- EriVan Bio
- EVerZom
- Evolutionary Biologics, Inc.
- Evomic Science LLC
- Evox Therapeutics, Ltd.
- EXO Biologics
- ExoCan Healthcare Technologies Pvt., Ltd.
- Exocel Bio
- Exogenus Therapeutics
- Exokeryx, Inc.
- ExoProTher Medical
- ExoQure
- EXORPHIA, Inc.
- ExosomeDx(biotechne)
- ExosomePlus
- Exosome Sciences
- ExoStemTech Co., Ltd.
- ExoVectory
- ExSURE Pvt. Ltd.
- Florica Therapeutics
- HansaBioMed Life Sciences, Ltd.
- ILIAS Biologics, Inc.
- INEXOPLAT, Inc.
- Innocan Pharma
- Innovex Therapeutics, SL
- INOVIQ, Ltd.
- Irazu Oncology
- Izon Science, Ltd.
- Kimera Labs, Inc.
- Leading Biology, Inc.
- LifeSpan Biosciences, Inc.
- Lonza Group, Ltd.
- Mantra Bio
- Mercury Bio
- Mercy Bioanalytics
- Micregen, Ltd.
- Microgentas
- miR Scientific
- Liver EV Liquid Biopsy Platform
- MyBioSource, Inc.
- Nano 24(OBCDCT24)
- NanoSomiX, Inc.
- Nanovex Biotechnologies
- NeurExo Sciences
- NeuroDex, Inc.
- Norgen Biotek Corporation
- Novaxomx GmbH
- Novus Biologicals
- NurExone Biologic, Inc.
- Oasis Diagnostics Corporation
- NX Prenatal, Inc.
- OmniSpirant Therapeutics
- OncoXome, Inc.
- Paracrine Therapeutics Pte, Ltd.
- QIAGEN
- Reactive Medical Labs
- ReNeuron
- RION Aesthetics, Inc.
- Rivela Diagnostics
- RoosterBio, Inc.
- ShiftBIO
- SOL Bio Corporation
- SomesTech
- Stem Cell Medicine, Ltd.
- System Biosciences
- Theoria Science, Inc.
- TheraXyte
- Thermo Fisher Scientific
- TheraXyte Bioscience
- The Tiny Cargo Company
- TransGen Biotech, Co., Ltd.
- Tymora Analytical
- Unicyte AG
- Urvogelbio Pvt, Ltd.
- Versatope Therapeutics
- VesiCURE Therapeutics
- Vesigen Therapeutics, Inc.
- VivaZome Therapeutics
- ZEO ScientifiX, Inc.
- Xosomix
도표 색인
표 색인
KSA
EXECUTIVE SUMMARY
Exosomes are extracellular vesicles (EVs) originating from endosomes, with sizes ranging from 30 to 150 nanometers. Secreted by nearly all cell types, exosomes play a key role in cell communication by carrying cell-specific proteins, lipids, and nucleic acids that are selectively absorbed by recipient cells.
Recent advancements in exosome technology are driving growth in their application across liquid biopsy, precision medicine, and regenerative medicine. Cancer-derived exosomes, in particular, are valuable for their ability to regulate angiogenesis, metastasis, and immunity, making them crucial for cancer detection, diagnosis, and treatment selection.
Exosome cargos offer prognostic insights for various diseases, including cardiovascular, renal, neurodegenerative, and metabolic disorders, as well as cancer. The discovery of numerous biomolecules within exosomes has spurred extensive research into their use as cancer biomarkers for detection, monitoring, and treatment.
Exosomes are present in many biofluids such as serum, plasma, urine, and saliva, making them ideal for minimally invasive diagnostics. They also serve as prognostic indicators and predictors of treatment responses. Furthermore, exosomes are being investigated for therapeutic use. For instance, exosomes can be engineered to carry therapeutic siRNA or proteins for targeted treatment of diseases caused by defective or missing molecules. Mesenchymal stem cell (MSC) derived exosomes have shown potential in reducing inflammation, preventing scar tissue formation, and modulating immune responses.
The exosome field, once underappreciated, is now rapidly evolving. Recent publications highlight the significant contributions of U.S. authors and Chinese researchers, with Dr. Susanne Gabrielsson from the Karolinska Institutet and Unicyte AG leading in relevant scientific literature.
BioInformant's global strategic report details the burgeoning exosome market, including trends in patents, grants, publications, and clinical trials. It covers industry partnerships, M&A activities, and financing, with insights into the competitive landscape and market forecasts through 2030.
Exosome-based diagnostics and therapeutics are expanding, with 388 clinical trials currently underway. Although no exosome therapeutics have received marketing approval yet, the first five products are anticipated by 2029. Exosomes offer promising advantages over traditional therapies, including targeted delivery, reduced side effects, and avoidance of immune detection.
In addition to medical applications, exosomes are also being used within cosmetics to promote skin rejuvenation, wound healing, scar revision, and hair restoration. Two exosome-based diagnostics have already received Fast Track approval from the U.S. FDA.
This comprehensive report provides:
- Market analysis for exosome therapeutics, diagnostics, product/services, manufacturing technologies, and cosmetic applications
- The clinical trial pipeline for exosome therapeutics, including both naive and engineered exosomes
- Approved and forthcoming products leveraging exosome diagnostics
- Clinical trial activity by type, region, phase, and sponsor
- Analysis of key industry metrics, including scientific publications, patents, grants, and clinical trials
- Key funding events, including M&A, financing events, co-development agreements, and IPOs
- Strategic partnerships and competitive insights
- Market size figures, broken down by market segment and geography, with forecasts through 2030
- Industry trends and future directions
This report is designed to inform market competitors who are developing exosome therapeutics, diagnostics, research products, manufacturing technologies, cosmeceuticals, and of course, ready-to-use exosomes. With the competitive nature of the exosome market, this report offers a valuable resource to stay informed and seize opportunities, without spending countless hours on research.
TABLE OF CONTENTS
1. REPORT OVERVIEW
- 1.1. Statement of the Report
- 1.2. Target Demographic
- 1.3. Report Sources
- 1.4. Purpose of the Report
- 1.5. Executive Summary
- 1.6. Introduction
2. BIOLOGY & FUNCTIONS OF EXOSOMES: AN OVERVIEW
- 2.1. Structure of an Exosome
- 2.1.1. Molecular Contents of Exosomes
- 2.1.1.1. Proteins in Exosomes
- 2.1.1.2. Lipid Contents of Exosomes
- 2.1.1.3. Nucleic Acids in Exosomes
- 2.1.2. Membrane and Lumen Components of Exosomes
- 2.1.3. Classification of Exosomes by Origin
- 2.1.3.1. Natural Exosomes
- 2.1.3.1.1. Isolation of Natural Exosomes
- 2.1.3.2. Modified Exosomes
- 2.1.3.2.1. Types of Therapeutic Cargos Loaded into Exosomes
- 2.1.3.2.2. Biomedical Applications of Engineered Exosomes
- 2.1.4. Synthetic Exosomes
- 2.2. Differences between Cell Therapy and Gene Therapy
- 2.3. The Shift from Cell Therapy to Exosome Therapy
- 2.4. Exosomes in the Next Ten Years
3. EXOSOME ENGINEERING: A NEW TECHNOLOGY PLATFORM
- 3.1. Interior Modification
- 3.1.1. Pre-Isolation Interior Modification Methods
- 3.1.2. Incubation
- 3.1.3. Gene Editing
- 3.1.4. Post-Isolation Interior Modification Methods
- 3.2. Surface Modifications
- 3.2.1. Surface Modification through Parent Cell
- 3.2.2. Direct Surface Modification
- 3.2.3. Displayed Molecules in Exosomes
- 3.3. Interior Modification
- 3.3.1. Pre-Isolation Interior Modification
- 3.3.2. Post-Isolation Modification Methods
- 3.4. An Exosome Showing Modified Surface and Modified Interior
- 3.4.1. Examples of Hydrophilic Cargo Loaded into Exosome Lumen
4. SCIENTIFIC PUBLICATIONS ON EXOSOMES
- 4.1. Publication Trends of Exosome Diagnostics and Therapeutics
- 4.2. PubMed Publications on Therapeutic Exosomes by Loading Technology
- 4.3. PubMed Papers on Exosome Isolation & Purification by Technology
- 4.4. PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
- 4.5. Distribution of Exosome Publications by Disease Type
- 4.6. Exosome Publications by Cancer Type
5. EXOSOME PATENTS: AN OVERVIEW
- 5.1. Exosome Patent Publications over Time
- 5.2. Exosome Patents: Therapeutic vs. Diagnostics
- 5.3. Exosome Patent Applications by Exosome Source
- 5.4. Patents/Patent Applications by Isolation/Purification Technologies
- 5.5. Patents/Patent Applications by Type of Cargo
- 5.6. Patents/Patent Applications by Cargo Loading Methods
- 5.7. Patents/Patent Applications by Therapy Area
- 5.8. Leading Assignees of Exosome Patents
- 5.8.1. Types of Patented Isolation/Preparations Technologies by Assignees
- 5.8.2. Types of Cargos Employed by Assignees
- 5.8.3. Cargo Loading Methods by Assignees
- 5.8.4. Therapy Areas by Assignees
- 5.8.5. Assignee Categories
- 5.9. Exosome Patent Applications by Jurisdiction
- 5.10. Exosome Patent Applicants
- 5.11. Exosome Patent Inventors
- 5.12. Exosome Patent Owners
- 5.13. Legal Status of Exosome Patents
6. EXOSOMES: CLINICAL TRIAL LANDSCAPE
- 6.1. Exosome Clinical Trials by Phase of Study
- 6.2. Exosome Clinical Trials by Funder Type
- 6.3. Exosome Clinical Trials by Technology
- 6.4. Current Status of Clinical Trials using Exosomes in Treating Diseases
- 6.5. Clinical Trials using Exosomes for Diagnostic Studies
- 6.6. Major Exosome R&D Companies
- 6.7. Exosome Therapeutics in Preclinical Development
7. EXOSOME ISOLATION/PURIFICATION TECHNOLOGIES: BRIEF OVERVIEW
- 7.1. Ultracentrifugation (UC)
- 7.1.1. Differential Ultracentrifugation
- 7.1.2. Density Gradient Ultracentrifugation (DGU)
- 7.2. Ultrafiltration (UF)
- 7.2.1. Tandem-Configured Ultrafiltration
- 7.2.2. Sequential Ultrafiltration
- 7.3. Size Exclusion Chromatography (SEC)
- 7.4. Polymer Precipitation Method
- 7.5. Immunoaffinity Capture Method
- 7.6. Aptamer-Based Method
- 7.7. Microfluidic Technique
8. PROPRIETARY TECHNOLOGY PLATFORMS OF EXOSOME COMPANIES
- 8.1. Description of Select Exosome Technology Platforms
- 8.1.1. AGLE-102
- 8.1.2. Hybridosome
- 8.1.3. AB126
- 8.1.4. CAP-1002 (Deramiocel)
- 8.1.5. REGENT
- 8.1.6. ExoFlo
- 8.1.7. DeliverEX
- 8.1.8. EXOVEX
- 8.1.9. ExoSCRT
- 8.1.10. LEAP
- 8.1.11. ExoDx
- 8.1.12. EXPLOR
- 8.1.13. Exo-Target
9. EXOSOME ENGINEERING TECHNOLOGIES: AN OVERVIEW
- 9.1. Incubation Method
- 9.2. Transfection Method
- 9.3. Sonication Method
- 9.4. Electroporation Method
- 9.5. Extrusion Method
- 9.6. Freeze/Thaw Method
- 9.7. Genetic Engineering Method
10. THERAPEUTIC APPLICATIONS OF EXOSOMES: A BRIEF OVERVIEW
- 10.1. Key Players in the Exosome Therapeutic Space
- 10.1.1. EXO-CD24 from Nano24 (OBCTCD24)
- 10.1.2. The Hemopurifier
- 10.1.2.1. Hemopurifier in Cancer
- 10.1.2.2. Hemopurifier in Infectious Diseases
- 10.1.3. REGENT from Carmine Therapeutics
- 10.1.4. Exosome Customization Technology from Ciola
- 10.1.5. CAP-1002 (Deramioce) from Capricor Therapeutics
- 10.1.6. EXPLOR from ILIAS Biologics
- 10.1.7. AB126 from Aruna Bio
- 10.1.8. AGLE-102 from Aegle Therapeutics
- 10.1.9. OmniSomes from OmniSpirant Therapeutics
- 10.1.10. EXO-101 from Exogenus Therapeutics
- 10.1.11. Purified Exosome Product (PEP) from RION
11. DIAGNOSTIC APPLICATIONS OF EXOSOMES
- 11.1. Advantages in Diagnostic Applications
- 11.2. Major Indications Focused for Diagnosis
- 11.3. Most Common Targeted Exosome Biomarkers
- 11.3.1. Exosomal Proteins for Diagnostic Applications
- 11.3.2. Exosomal miRNAs as Cancer Diagnostic Agents
- 11.4. Diagnostic Exosome Research
- 11.5. Key Players in the Development of Exosome Diagnostics
- 11.5.1. LiquidScan from BioFluidica
- 11.5.2. ExoEnrich from ExoCan
- 11.5.3. ExoDx Prostate Test from Exosome Diagnostics, Inc.
- 11.5.4. TauSome Test from Exosome Sciences
- 11.5.5. Cancer Diagnosis from Exosomics S.p.A
- 11.5.6. Guardant360 CDx from Guardant Health
- 11.5.7. Liver Cancer Detection study by Mursla Bio
- 11.5.8. BDE Biomarker Assay from NanoSomiX
- 11.5.9. ExoScreen Assay from Theoria Science
12. APPLICATIONS OF EXOSOMES IN AESTHETICS
- 12.1. Aesthetic Exosome Treatments
- 12.1.1. Exosomes in Facial Rejuvenation
- 12.1.2. Exosomes in Hair Restoration
- 12.1.3. Exosomes in Scar Reduction
- 12.1.4. Exosomes in Breast Augmentation
- 12.2. Sources of Exosomes for Aesthetic Use
- 12.3. Science behind Dermatologically Relevant Exosomes
- 12.4. Key Players & Products
- 12.5. Popular Exosome-Based Aesthetics
- 12.5.1. AnteAGE Pro System
- 12.5.2. ExoCR from Cartessa
- 12.5.3. ELEVAI enfinity from ELEVAI Labs
- 12.5.4. EXO PLUS from Exoceuticals
- 12.5.5. Vive from Kimera Labs
- 12.5.6. CALM Serum from RION Aesthetics
- 12.5.7. ASCE Exosomes from ExoCoBio
13. DEALS AND FUNDRAISING IN EXOSOME SPACE
- 13.1. Venture Capital Funding for Exosome companies
- 13.1.1. EXO Biologics
- 13.1.2. Exogenus Therapeutics
- 13.1.3. INEXOPLAT
- 13.1.4. Mantra Bio
- 13.1.5. Anjarium Biosciences
- 13.1.6. Evox Therapeutics, Ltd.
- 13.1.7. ILIAS Biologics
- 13.1.8. ExoCoBio, Inc.
- 13.1.9. Aegle Therapeutics
- 13.1.10. Evox Therapeutics
- 13.1.11. Evox Therapeutics
- 13.1.12. Codiak BioSciences
- 13.1.13. Codiak BioSciences
- 13.1.14. Exosome Diagnostics
- 13.1.15. Exosome Diagnostics, Inc
- 13.2. Partnership Deals in Exosome Space
- 13.2.1. Cytiva & Rooster Bio
- 13.2.2. SomesTech & ConvEyXO
- 13.2.3. RoosterBio, Inc. & FUJIFILM Diosynth Biotechnologies
- 13.2.4. Evox Therapeutics & Eli Lilly
- 13.2.5. Exopharm & Astellas
- 13.2.6. Univercells Technologies & RoosterBio
- 13.2.7. AgeX Therapeutics & UCI
- 13.2.8. VivaZome & La Trobe University
- 13.2.9. Evotec SE & Curexsys GmbH
- 13.2.10. Bio-Techne & QIAGEN
- 13.2.11. InnoCan Pharma & Recipharms
- 13.2.12. Codiak BioSciences & Sarepta
- 13.2.13. Evox Therapeutics & Takeda
- 13.2.14. PureTech & Roche
- 13.2.15. Evox Therapeutics & Boehringer Ingelheim
- 13.2.16. Sarpeta Therapeutics & Codiak Biosciences
- 13.2.17. Navigo Proteins & MDimune
- 13.2.18. Jazz Pharmaceuticals & Codiak BioSciences
- 13.2.19. Exosome Diagnostics & Intezyne
- 13.2.20. Evox Therapeutics & Boehringer Ingelheim
- 13.3. Acquisition Deals
- 13.3.1. ExoCoBio & BENEV
- 13.3.2. Evox Therapeutics & Codiak Biosciences' Technology
- 13.3.3. Lonza & Exosomics
- 13.3.4. Lonza & Codiak Biosciences
- 13.3.5. Bio-Techne Corporation & Exosome Diagnostics
- 13.3.6. Lonza & HansaBioMed
- 13.4. Licensing Deals
- 13.4.1. EVerZom & Erganeo
- 13.4.2. Elevai Labs & Yuva Biosciences
- 13.4.3. TOPPAN & Dai Nippon Toryo
- 13.4.4. Carnegie Mellon University (CMU) & Coya Therapeutics
- 13.4.5. INOVIQ, Ltd. & ResearchDx, Inc.
- 13.4.6. ATUM & Codiak BioSciences
- 13.4.7. Johns Hopkins University & Capricor Therapeutics
- 13.4.8. Evox Therapeutics & Eli Lily
- 13.4.9. Codiak BioSciences & Sarepta
- 13.4.10. VivaZome Therapeutics & University of Adelaide
- 13.4.11. Evox Therapeutics & Takeda
- 13.4.12. CEVEC & Evox Therapeutics
- 13.4.13. Orgenesis & Excella Bio
- 13.4.14. System Biosciences & QIAGEN
- 13.4.15. PureTech Health & 3D Biotechnologies
- 13.5. IPO
- 13.5.1. Elevai Labs
- 13.5.2. Codiak Biosciences
- 13.5.3. Codiak Biosciences
- 13.5.4. Codiak BioSciences
14. EXOSOME MARKET ANALYSIS
- 14.1. Market for Exosome Therapeutics
- 14.2. The Global Market for Ready-to-Use Purified Exosomes by Type
- 14.2.1. Market Size of Exosomes by Parent Cell Type
- 14.3. Market for Exosome Diagnostics
- 14.4. Global Exosome Technologies Market by Product Type
- 14.5. Global Exosome-Based Aesthetics (Cosmeceuticals) Market
- 14.6. The Overall Market for Exosomes
- 14.7. The Market Driver of Exosome Therapies
15. PROFILES OF EXOSOME MARKET COMPETITORS
- 15.1. 101 Bio
- 15.1.1. PureExo Exosome Isolation Kit
- 15.2. Abbexa, Ltd.
- 15.3. AcouSort AB
- 15.3.1. Technology: Acoustic Separation
- 15.3.2. EIC Award
- 15.4. Aegle Therapeutics
- 15.4.1. Research & Development
- 15.5. Aethlon Medical, Inc.
- 15.6. Akrivis Health Care Pvt., Ltd.
- 15.7. AM BioTech
- 15.7.1. Bio-Pulsed Technology
- 15.7.2. ExoGiov
- 15.7.3. LA EXO Exosome Cosmetics
- 15.8. AMS Biotechnology, Ltd. (AMSBIO)
- 15.9. AnteAGE
- 15.9.1. At-Home Skincare Products
- 15.9.2. At-Home Brow & Lash Products
- 15.9.3. VRS Box (6 Pack) [$150]
- 15.9.4. Professional Skincare Products
- 15.9.5. Growth Factor Microneedling Products
- 15.9.6. Stem Cell Facial Microchanneling Products
- 15.9.7. Medical Skin Care Products
- 15.9.8. Growth Factor Skin Treatment Products
- 15.9.9. Growth Factor Hair Regeneration Products
- 15.10. Aposcience AG
- 15.10.1. Wound Healing
- 15.10.2. Myocardial Infarction
- 15.11. Aruna Bio
- 15.11.1. AB126 (Neural Exosome)
- 15.12. BENEV Company, Inc. (ExoCoBio)
- 15.12.1. Exosome Regenerative Complex
- 15.12.2. Exosome Regenerative Complex +
- 15.12.3. EXO-XOM Facial
- 15.13. BioCat GmbH
- 15.13.1. ExoQuick Exosome Precipitation
- 15.13.2. Exosome RNA & DNA Purification
- 15.13.3. Exosome RNA Amplification & Profiling
- 15.13.4. Exosome Quantification
- 15.13.5. Exosome Antibody Array
- 15.13.6. ExoGlow EV Labeling Kits
- 15.13.7. Exosome Engineering
- 15.14. BioFluidica
- 15.14.1. LiquidScan
- 15.14.2. Exosome Isolation
- 15.15. Biological Dynamics, Inc.
- 15.15.1. Verita Technology
- 15.15.2. ExoVerita Pro Exosome Enrichment Platform
- 15.15.3. Exosome Isolation & Analysis Services
- 15.16. Biorbyt, Ltd.
- 15.17. Bioscience Institute
- 15.17.1. Bioscience Clinic Middle East
- 15.17.2. Bioscience Genomics
- 15.17.3. Services
- 15.17.3.1. ExoSkin Therapy
- 15.17.3.2. ExoHair Therapy
- 15.17.3.3. ExoJoints Therapy
- 15.17.3.4. ExoMale Therapy
- 15.17.3.5. ExoFemale Therapy
- 15.17.3.6. XOLINE Exosome Cosmetics
- 15.18. Biosynth International, Inc.
- 15.18.1. ME Kit (Microvesicle Extraction Kit)
- 15.19. BreStem Therapeutics, Inc.
- 15.20. Capricor Therapeutics
- 15.20.1. Portfolio
- 15.20.2. StealthX Technology
- 15.21. Carmine Therapeutics
- 15.22. Cellarcus Biosciences, Inc.
- 15.22.1. vFC Vesicle Analysis Assays
- 15.22.2. vTAG Antibodies
- 15.22.3. Vesicles and Vesicle Assay Standards
- 15.23. Cell Care Therapeutics
- 15.24. Cells for Cells
- 15.24.1. Current Clinical Trial using Exosomes
- 15.25. Cell Guidance Systems, Ltd.
- 15.25.1. Exosome Products
- 15.25.2. Exo-spin Purification
- 15.25.3. ExoLISA Technology: Exosome Detection
- 15.25.4. Exosome Validated Antibodies
- 15.25.5. Instant Exosomes
- 15.25.6. NTA Size Profiling Service
- 15.26. Ciloa
- 15.26.1. Antibodies against Undruggable Targets
- 15.26.2. Adjuvant & Virus-Free Vaccines
- 15.26.3. Virus-Free Therapeutic Vectors
- 15.26.4. Technology
- 15.27. ConvEyXO
- 15.27.1. Exo-Harvest Technology
- 15.27.2. XomeXBio Technology
- 15.28. Craif, Inc.
- 15.28.1. NANO IP (Nano Intelligence Platform)
- 15.29. Creative Bioarray
- 15.29.1. Exosome Antibodies
- 15.29.2. Exosome DNA-RNA Extraction Kits
- 15.29.3. Exosome Isolation Tools
- 15.29.4. Exosome Standards
- 15.29.5. Fluorescent Exosome Standards
- 15.29.6. Liquid Biopsy
- 15.29.7. Exosome Research Services
- 15.30. Creative Biostructure
- 15.30.1. Exosome Products
- 15.30.2. Exosome Services
- 15.30.2.1. Exosome Isolation Services
- 15.30.2.2. Exosome Analysis Services
- 15.30.2.3. Exosome Characterization Services
- 15.30.2.4. Exosome Engineering Services
- 15.30.2.5. Exosome In Vitro Functional Assay
- 15.30.2.6. Exosome In Vitro Functional Assay
- 15.31. Creative Biolabs
- 15.31.1. Exosome Products
- 15.31.2. Exosome Isolation Tools
- 15.31.3. Exosome Capture & Quantification Kits
- 15.31.4. Exosome Antibody Products
- 15.31.5. Exosome Standards
- 15.31.6. Exosome Labeling Kits
- 15.31.7. Exosomes Surface Modification Kits
- 15.31.8. Exosome Identification Kits
- 15.31.9. Exosome Marker cDNA Plasmid Products
- 15.31.10. Exosome Release Modulation Reagents
- 15.31.11. LipidSync Exosomes
- 15.31.12. Exosome Services
- 15.32. Creative Medical Technology Holdings, Inc.
- 15.32.1. AmnioStem Stroke Therapy
- 15.33. Creative Proteomics
- 15.33.1. Exosome Services
- 15.34. CUSABIO Technology LLC
- 15.34.1. Exosome Isolation Kits
- 15.35. Diadem Biotherapeutics
- 15.36. Direct Biologics
- 15.36.1. ExoFlo
- 15.36.2. AmnioWrap
- 15.37. Elevai Labs, Inc.
- 15.37.1. ELEVAI enfinity
- 15.37.2. ELEVAI empower
- 15.37.3. ELEVAI Root Renewal System
- 15.38. Entelexo Biotherapeutics
- 15.39. EriVan Bio
- 15.39.1. Services
- 15.39.2. Research Products
- 15.40. EVerZom
- 15.40.1. EVerZom Platform
- 15.41. Evolutionary Biologics, Inc.
- 15.41.1. EXO ELIXIR
- 15.41.2. EVO GROW
- 15.41.3. EVO JEL
- 15.41.4. EXO RNA
- 15.41.5. EVO HYBRID
- 15.41.6. EXO PERIO
- 15.42. Evomic Science LLC
- 15.42.1. ExoEZ Exosome Isolation Kit
- 15.43. Evox Therapeutics, Ltd.
- 15.43.1. Gene Therapy
- 15.43.2. Gene Editing
- 15.43.3. RNA Therapeutics
- 15.43.4. Precision Therapeutic Targeting
- 15.43.5. Protein Therapeutics
- 15.43.6. Manufacturing Exosomes
- 15.43.7. Focus on Rare Diseases
- 15.44. EXO Biologics
- 15.44.1. Lead Product Candidate
- 15.45. ExoCan Healthcare Technologies Pvt., Ltd.
- 15.45.1. ExoEnrich
- 15.45.2. ExoEngineering
- 15.45.3. SAC-3D
- 15.45.4. Services
- 15.45.4.1. Multiphenotype Screen
- 15.45.4.2. Small Molecule Screening
- 15.45.4.3. Exo-BiDD
- 15.46. Exocel Bio
- 15.46.1. Services
- 15.46.1.1. Exosome Isolation via Ultracentrifugation
- 15.46.1.2. Nanoparticle Analysis for Size Distribution and Concentration
- 15.46.1.3. Custom Experiments with NTA
- 15.46.1.4. Custom Growth Factors Production
- 15.46.2. Products
- 15.46.2.1. Exovex REVIVE
- 15.46.2.2. Exovex RENEW
- 15.46.2.3. Exovex REVEAL
- 15.46.2.4. Exovex REFINE
- 15.46.2.5. Exovex RESTORE
- 15.46.2.6. Exovex EQUUSOME
- 15.46.2.7. Exovex CANISOME
- 15.46.2.8. Exovex FELISOM
- 15.47. Exogenus Therapeutics
- 15.47.1. Exo-101
- 15.47.2. ExoWound
- 15.48. Exokeryx, Inc.
- 15.48.1. Demeter EVPrep
- 15.48.2. ExoScan
- 15.49. ExoProTher Medical
- 15.50. ExoQure
- 15.50.1. Technology
- 15.50.2. Products
- 15.51. EXORPHIA, Inc.
- 15.51.1. Activation Technology to produce Prime-EV
- 15.51.2. Modification Technology to Produce Smart-EV
- 15.51.3. INPACT-EV Technology
- 15.51.4. EV Analysis Technology: EV-QUEST
- 15.51.5. EXORPHIA's Product Pipeline
- 15.52. ExosomeDx (biotechne)
- 15.52.1. ExoDx Prostate Test
- 15.52.2. Pharma Services
- 15.52.3. Biomarker Discovery Services
- 15.53. ExosomePlus
- 15.53.1. MSC-Derived Exosomes
- 15.53.2. ExoCope Technology
- 15.54. Exosome Sciences
- 15.54.1. TauSome (Exosomal Tau) Biomarker
- 15.55. ExoStemTech Co., Ltd.
- 15.55.1. Cartisome
- 15.55.2. EST-T-EXO
- 15.55.3. Hepatosome
- 15.55.4. Hypoxisome
- 15.55.5. Exosome Manufacturing Platform
- 15.55.6. Protein Loading & Delivery Platform
- 15.56. ExoVectory
- 15.56.1. Technology
- 15.56.2. Therapeutic Areas Focused
- 15.56.3. Exosome Immunotherapy for Cancer
- 15.56.4. Exosome Gene Therapy
- 15.57. ExSURE Pvt. Ltd.
- 15.58. Florica Therapeutics
- 15.59. HansaBioMed Life Sciences, Ltd.
- 15.59.1. Products
- 15.59.2. Services
- 15.60. ILIAS Biologics, Inc.
- 15.60.2. Cargo Loading Process
- 15.60.3. Exo-Target: Platform Technology
- 15.61. INEXOPLAT, Inc.
- 15.62. Innocan Pharma
- 15.62.1. Cannabidiol (CBD)-Loaded Exosomes
- 15.63. Innovex Therapeutics, SL
- 15.63.1. Research & Development
- 15.63.2. Vaccine against Plasmodium vivax malaria (PvRexVac)
- 15.63.3. Vaccine against COVID-19 (ExoCoVac)
- 15.63.4. Vaccine against PRRSV (PrrsvExoVac)
- 15.64. INOVIQ, Ltd.
- 15.64.1. NETs Technology
- 15.64.2. EXO-NET Pan Exosome
- 15.65. Irazu Oncology
- 15.66. Izon Science, Ltd.
- 15.66.1. qEV Isolation
- 15.66.2. qEV Automation
- 15.66.3. qEV Zenco
- 15.66.4. Robotic System for Diagnostic Development
- 15.66.5. qEV Magnetic Concentration Kit
- 15.66.6. Tunable Resistive Pulse Sensing (TRPS)
- 15.67. Kimera Labs, Inc.
- 15.67.1. Vive
- 15.67.2. Luxir & Luxir+
- 15.68. Leading Biology, Inc.
- 15.69. LifeSpan Biosciences, Inc.
- 15.70. Lonza Group, Ltd.
- 15.71. Mantra Bio
- 15.71.1. REVEAL
- 15.71.2. Partnering
- 15.72. Mercury Bio
- 15.72.1. The Chimeric yEV System
- 15.73. Mercy Bioanalytics
- 15.73.1. The Mercy Halo Test
- 15.74. Micregen, Ltd.
- 15.75. Microgentas
- 15.75.1. Products
- 15.75.1.1. Exo TFF
- 15.75.1.2. ExoFilter
- 15.75.1.3. ExoCAS-2 (Exosome Clustering and Scattering)
- 15.75.1.4. ExoPAS Advanced (Exosome Precipitation and Scattering)
- 15.75.1.5. miRQuick (Exosomal miRNA)
- 15.75.1.6. PIBEX System
- 15.75.1.7. Plant Exosomes for Cosmetics
- 15.75.1.8. Centella Asiatica Extracellular Vesicles (CICA EVs)
- 15.75.2. Services
- 15.76. miR Scientific
- 15.77. Mursla Bio
- 15.77.1. Liver EV Liquid Biopsy Platform
- 15.78. MyBioSource, Inc.
- 15.79. Nano 24 (OBCDCT24)
- 15.80. NanoSomiX, Inc.
- 15.81. Nanovex Biotechnologies
- 15.81.1. Technology
- 15.81.2. Synthetic Exosomes
- 15.82. NeurExo Sciences
- 15.82.1. Research & Development Programs
- 15.83. NeuroDex, Inc.
- 15.83.1. ExoSORT
- 15.83.2. Lumin-EV
- 15.83.3. Alpha-synuclein Assay
- 15.83.4. TDP43 Assay
- 15.83.5. Synaptic Protein Assay
- 15.83.6. Autophagy Assay
- 15.83.7. Biomarker Discovery Services
- 15.83.8. LuminEV Kit
- 15.84. Norgen Biotek Corporation
- 15.84.1. Exosome Kits
- 15.84.1.1. Intact Exosome Purification
- 15.84.1.2. RNA Isolation from Intact Exosomes
- 15.84.1.3. Exosome Purification, Exosome RNA and Free-Circulating RNA Isolation
- 15.84.1.4. RNA Isolation from Purified Intact Exosomes
- 15.84.1.5. Exosome Depletion
- 15.84.1.6. Exosome Labeling and Cleaning Kit
- 15.84.1.7. Isolation Services
- 15.84.1.8. Contract Manufacturing Services
- 15.85. Novaxomx GmbH
- 15.86. Novus Biologicals
- 15.86.1. Exosome Research Tools
- 15.87. NurExone Biologic, Inc.
- 15.88. Oasis Diagnostics Corporation
- 15.89. NX Prenatal, Inc.
- 15.90. OmniSpirant Therapeutics
- 15.90.1. OmniSome Therapeutic Platform
- 15.91. OncoXome, Inc.
- 15.91.1. OncoXome's Exosomes
- 15.92. Paracrine Therapeutics Pte, Ltd.
- 15.93. QIAGEN
- 15.93.1. exoEasy Maxi Kit
- 15.93.2. exoRNeasy Midi Kit
- 15.93.3. mercury LNA miRNA Focus PCR Panels
- 15.93.4. miRCURY Exosome Serum/Plasma Kit
- 15.94. Reactive Medical Labs
- 15.95. ReNeuron
- 15.95.1. CustomEX - A Customizable Exosome Platform
- 15.96. RION Aesthetics, Inc.
- 15.96.1. Products
- 15.96.1.1. INTENSE Serum
- 15.96.1.2. DAILY Serum
- 15.96.1.3. CALM Serum
- 15.96.1.4. HAIR Serum
- 15.97. Rivela Diagnostics
- 15.98. RoosterBio, Inc.
- 15.98.1. MSC-derived Exosomes
- 15.98.2. QuickShip Exosomes
- 15.98.3. QuickShip MSC and Exosome Media
- 15.98.4. XF Bioreactor MSC & EV Development Kits
- 15.98.5. XF Bioreactor MSC & EV Scale-Up Kits
- 15.98.6. XF Bioreactor MSC & EV Starter Kits
- 15.98.7. RoosterCollect-EV-CC
- 15.99. ShiftBIO
- 15.99.1. NSM Platform Technology
- 15.100. SOL Bio Corporation
- 15.100.1. Business Model
- 15.100.2. NeutraRelease Technology
- 15.100.3. ExoMain
- 15.100.4. ExoBead
- 15.101. SomesTech
- 15.101.1. Products & Solutions
- 15.101.1.1. ExoNP
- 15.101.1.2. ExoLoad
- 15.101.1.3. AI + DDS
- 15.102. Stem Cell Medicine, Ltd.
- 15.103. System Biosciences
- 15.103.1. Products
- 15.103.1.1. Exosome Isolation Products
- 15.103.1.2. Exosome Detection Products
- 15.103.1.3. Exosome Quantitation Products
- 15.103.1.4. Exosome Labeling Kit Products
- 15.103.1.5. Exosome Biomarker Discovery Products
- 15.103.1.6. Exosome Engineering & Design Products
- 15.103.2. Services
- 15.104. Theoria Science, Inc.
- 15.104.1. ExoScreen Technology
- 15.105. TheraXyte
- 15.105.1. TAXY - A Programmable Drug Delivery System
- 15.106. Thermo Fisher Scientific
- 15.106.1. Exosome Products for Testing & Research
- 15.107. TheraXyte Bioscience
- 15.108. The Tiny Cargo Company
- 15.109. TransGen Biotech, Co., Ltd.
- 15.109.1. Products
- 15.109.1.1. TransExo Cell Media Exosome Kit
- 15.109.1.2. TransExo Urine Exosome Kit
- 15.109.1.3. TransExo Serum/Plasma Exosome Kit
- 15.109.1.4. TransExo Serum/Plasma Exosome Total RNA Extraction Kit
- 15.109.1.5. TransExo Serum/Plasma Exosome Total miRNA Extraction Kit
- 15.110. Tymora Analytical
- 15.110.1. Services
- 15.110.1.1. Plasma Proteomics (PTMs)
- 15.110.1.2. Urine Proteomics
- 15.110.1.3. Saliva Proteomics
- 15.110.1.4. Tissue Proteomics
- 15.111. Unicyte AG
- 15.112. Urvogelbio Pvt, Ltd.
- 15.113. Versatope Therapeutics
- 15.113.1. Technology
- 15.113.2. Universal Influenza Vaccine
- 15.114. VesiCURE Therapeutics
- 15.114.1. modEXO Platform
- 15.114.2. dilEVery Delivery System
- 15.115. Vesigen Therapeutics, Inc.
- 15.115.1. ARMMs
- 15.115.2. Disease Areas of Focus
- 15.115.2.1. Ocular
- 15.115.2.2. Immunology
- 15.115.2.3. Neurology
- 15.115.2.4. Hematology
- 15.116. VivaZome Therapeutics
- 15.116.1. VivaZome's Clinical Targets
- 15.117. ZEO ScientifiX, Inc.
- 15.117.1. Aesthetic Exosomes
- 15.117.2. PPX
- 15.118. Xosomix
INDEX OF FIGURE
- FIGURE 2.1: Classification of Extracellular Vesicles
- FIGURE 2.2: Exosome Formation
- FIGURE 2.3: Exosome Uptake by Target Cells
- FIGURE 2.4: Structure of an Exosome
- FIGURE 2.5: Membrane Lumen Components of Exosomes
- FIGURE 2.6: Classification of Exosomes by Origin
- FIGURE 2.7: Exosome Isolation Methods
- FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display
- FIGURE 3.1: Pre-Isolation Interior Modification Methods
- FIGURE 3.2: Post-Isolation Interior Modification Methods
- FIGURE 3.3: Surface Modification through Parent Cell
- FIGURE 3.4: Direct Surface Modification
- FIGURE 3.5: Pre-Isolation Interior Modification Methods
- FIGURE 3.6: Post-Isolation Interior Modification Methods
- FIGURE 3.7: An Engineered Exosome showing Surface and Interior Modifications
- FIGURE 4.1: Number of PubMed.gov Publications, 2000-2024
- FIGURE 4.2: Publication Trends of Exosome Diagnostics and Therapeutics
- FIGURE 4.3: Number of PubMed Papers on Exosome Cargo-Loading by Technology
- FIGURE 4.4: PubMed Papers on Exosome Isolation & Purification by Technology
- FIGURE 4.5: PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
- FIGURE 4.6: Distribution of Exosome Publications by Disease Type
- FIGURE 4.7: Exosome Publications by Cancer Type
- FIGURE 5.1: Exosome Patent Publications over Time, 2000-June 2024
- FIGURE 5.2: Exosome Patents: Therapeutic vs. Diagnostics
- FIGURE 5.3: Exosome Patents/Patent Applications by Exosome Sources
- FIGURE 5.4: Patents/Patent Applications by Isolation-Preparation Technologies
- FIGURE 5.5: Patents/Patent Applications by Type of Cargo
- FIGURE 5.6: Patents/Patent Applications by Cargo Loading Methods
- FIGURE 5.7: Patents/Patent Applications by Therapy Area
- FIGURE 5.8: Leading Assignees of Exosome Patents
- FIGURE 5.9: Top Five Countries with Exosome Patents
- FIGURE 6.1: Percent Share of Clinical Trials by Application
- FIGURE 7.1: Schematic of Differential Ultracentrifugation
- FIGURE 7.2: Schematic of Density Gradient Ultracentrifugation
- FIGURE 7.3: Schematic of Tandem Configured Ultrafiltration
- FIGURE 7.4: Sequential Ultrafiltration
- FIGURE 7.5: Schematic of Size Exclusion Chromatography
- FIGURE 7.6: Schematic of Polymer Precipitation Method
- FIGURE 7.7: Schematic of Immunoaffinity Capture Method
- FIGURE 7.8: Diagram of Working Principle of Microfluidic Device
- FIGURE 9.1: Schematic of Incubation Method of Drug Loading
- FIGURE 9.2: Schematic of Transfection Method
- FIGURE 9.3: Schematic Illustration of Sonication Method
- FIGURE 9.4: Schematic Illustration of the Principle of Electroporation
- FIGURE 9.5: Schematic Illustration of Drug Loading by Extrusion Method
- FIGURE 9.6: Schematic Illustration of Genetic Modification of Exosome
- FIGURE 10.1: Schematic Illustration of the Structure of EXO-CD24
- FIGURE 10.2: Aethlon's Hemopurifier
- FIGURE 10.3: Ciola's Unique in vivo Technology
- FIGURE 10.4: Schematic of EXPLOR
- FIGURE 10.5: CNS Specificity of AB126
- FIGURE 10.6: OmniSomes from OmniSpirant
- FIGURE 10.7: EXO-101 from Exogenus
- FIGURE 11.1: Great Things in Tiny Packages
- FIGURE 11.2: Major Indications Focused for Diagnosis
- FIGURE 11.3: LiquidScan from BioFluidica
- FIGURE 11.4: Exosome Isolation by ExoEnrich
- FIGURE 11.5: Features of ExoDx Prostate Test
- FIGURE 11.6: ExoScreen Assay from Theoria Science
- FIGURE 12.1: Exosomes in Facial Rejuvenation using DermaPen
- FIGURE 12.2: Exosome Therapy for Hair Restoration
- FIGURE 12.3: Exosomes in Scar Reuction
- FIGURE 12.4: AnteAGE Pro System
- FIGURE 12.5: ExoCR from Cartessa
- FIGURE 12.6: ELEVAI enfinity
- FIGURE 12.7: EXO PLUS from Exoceuticals
- FIGURE 12.8: Vive from Kimera Labs
- FIGURE 12.9: CALM Serum from RION Aesthetics
- FIGURE 12.10: ASCE Exosomes from ExoCoBio
- FIGURE 14.1: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
- FIGURE 14.2: Global Market for Ready-to-Use Exosomes by Type, 2023
- FIGURE 14.3: Global Exosome Therapy Market by Parent Cell Type, 2023
- FIGURE 14.4: Global Market for Exosome Diagnostics by Geography, 2023-2031
- FIGURE 14.5: Global Exosome Technologies Market by Products, 2023-2031
- FIGURE 14.6: Global Market for Exosome-based Aesthetic Products by Segment
- FIGURE 14.7: The Overall Exosome Market by Segment, 2031
- FIGURE 15.1: Aethlon's Hemopurifier
- FIGURE 15.2: qEV Zenco for Therapeutic Development
- FIGURE 15.3: Robotic System for Diagnostic Development
INDEX OF TABLES
- TABLE 2.1: Number of Molecular Contents identified in Exosomes
- TABLE 2.2: Proteins Identified in Exosomes
- TABLE 2.3: Common Lipid Contents of Exosomes
- TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes
- TABLE 2.5: Types of Therapeutic Cargos Loaded into Exosomes
- TABLE 2.6: Differences between Cell Therapy and Exosome Therapy
- TABLE 3.1: Hydrophobic Cargo Incorporated in Exosome Mmbrane
- TABLE 3.2: Examples of Hydrophilic Cargo Loaded into Exosome Lumen
- TABLE 5.1: Exosome Patent Applications by Jurisdiction as of June 23, 2024
- TABLE 5.2: Exosome Patent Applicants
- TABLE 5.3: Exosome Patent Inventors
- TABLE 5.4: Exosome Patent Owners
- TABLE 5.5: Legal Status of Exosome Patents as of June 22, 2024
- TABLE 6.1: Exosome Clinical Trials by Phase of Study
- TABLE 6.2: Exosome Clinical Trials by Funder Type
- TABLE 6.3: Exosome Clinical Trials by Technology
- TABLE 6.4: Current Status of Clinical Trials using Exosomes in Treating Diseases
- TABLE 6.5: Clinical Trials using Exosomes for Diagnostic Studies
- TABLE 6.6: Major Exosome R&D Companies
- TABLE 6.7: Exosome Therapeutics in Preclinical Development
- TABLE 8.1: Exosome Technology Platforms Developed by Commercial Companies
- TABLE 10.1: Key Players in Therapeutic Exosome Research
- TABLE 11.1: Most Common Targeted Exosome Biomarkers
- TABLE 11.2: Exosomal Proteins for Diagnostic Applications
- TABLE 11.3: Exosomal miRNAs as Cancer Diagnostic Agents
- TABLE 11.4: A Sample of Exosome Diagnostic Clinical Trials
- TABLE 11.5: Key Players in the Development of Exosome Diagnostics
- TABLE 12.1: Key Players in Exosome-based Aesthetics
- TABLE 13.1: Venture Capital Funding raised by Exosome Companies
- TABLE 13.2: Partnership/Collaboration Deals in Exosome Space
- TABLE 13.3: Acquisition Deals in Exosome Space
- TABLE 13.4: Licensing Deals in Exosome Space
- TABLE 13.5: Exosome Companies raising IPO Funds
- TABLE 14.1: Likely-to-be Approved Exosome Therapeutics between 2026 and 2029
- TABLE 14.2: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
- TABLE 14.3: Global Market for Ready-to-Use Exosomes by Type, 2023-2031
- TABLE 14.4: Global Exosome Therapy Market by Parent Cell Type, 2023-2031
- TABLE 14.5: Global Market for Exosome Diagnostics by Geography, 2023-2031
- TABLE 14.6: Global Exosome Technologies Market by Products, 2023-2031
- TABLE 14.7: Global Market for Exosome-based Aesthetic Products by Segment
- TABLE 14.8: The Overall Market for Exosomes
- TABLE 15.1: Aegle's Product Pipeline
- TABLE 15.2: Aruna Bio's Product Pipeline
- TABLE 15.3: BreStem Therapeutics' Product Pipeline
- TABLE 15.4: Capricor's Multi-Stage Pipeline
- TABLE 15.5: Entelexo's Pipeline
- TABLE 15.6: Evox Therapeutics' Product Pipeline
- TABLE 15.7: EXO Biologic's Product Pipeline
- TABLE 15.8: EXORPHIA's Product Pipeline
- TABLE 15.9: ExoStemTech's Pipeline Products
- TABLE 15.10: ILIAS' Product Pipeline
- TABLE 15.11: INOVIQ's Development Pipeline
- TABLE 15.12: NeurExo's Research & Development Programs
- TABLE 15.13: NeuroDex's Pipeline
- TABLE 15.14: ShiftBIO's Natural Drug Delivery Platform-based Programs
- TABLE 15.15: Unicyte's Pipeline
